Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 24;23(1):270.
doi: 10.1186/s12885-023-10754-0.

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

Haohao Lu  1   2 , Qing Ye  3 , Chuansheng Zheng  4   5 , Li Fan  2   6 , Xiangwen Xia  1   2
Affiliations

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

Haohao Lu et al. BMC Cancer. .

Abstract

Background: Since renal cell carcinoma(RCC) is insensitive to conventional chemoradiotherapy, molecularly targeted drugs are commonly used treatments for unresectable advanced RCC. The aim of this study was to explore the efficacy and safety of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced RCC.

Methods: This study included 98 patients with unresectable advanced RCC who were treated in Union Hospital from January 2015 to December 2018, and they met the criteria. They were divided into two groups: TACE + Sunitinib group (N = 47) and Sunitinib group (N = 51). We conducted a retrospective study to analyze the efficacy and safety of the two groups of patients.

Results: (1)TACE + Sunitinib group: 4 patients (8.5%) achieved CR, 27 patients (57.5%) achieved PR, 9 patients (19.1%) achieved SD, and 7 patients (14.9%) achieved PD. Sunitinib group, 0 patients (0%) achieved CR, 20 patients (39.2%) achieved PR, 14 patients (27.5%) achieved SD, and 17 patients (33.3%) achieved PD. (P = 0.017) (2)ORR: TACE + sunitinib group, 66.0%; sunitinib group, 39.2%. (P = 0.009) (3)DCR: TACE + sunitinib group, 85.1%; sunitinib group, 66.7%. (P = 0.038) (4) In the TACE + sunitinib group, mPFS was 15.6 months, mOS was 35.0 months; in the sunitinib group, the mPFS was 10.9 months, mOS was 25.7 months. (P < 0.001) (5) The incidence of abdominal pain, fever, and vomiting was higher in the TACE + sunitinib group than in the sunitinib group (abdominal pain: 55.3% vs. 13.7%; fever: 61.7% vs. 7.8%; vomiting: 40.4% vs. 19.6%; P < 0.05). The technical success rate of TACE in TACE + Sunitinib group is 100%.

Conclusions: The TACE + sunitinib group had higher ORR and DCR, longer OS and PFS than the sunitinib alone group. TACE combined with sunitinib can play a complementary role and is a safe and effective treatment for advanced RCC.

Keywords: Molecular targeted therapy; Renal artery embolization; Renal cell carcinoma; Sunitinib; TACE; Transarterial embolization; Transcatheter arterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and company that could be construed as influencing the position presented in this manuscript.

Figures

Fig. 1
Fig. 1
Flow Chart of Patient Enrollment
Fig. 2
Fig. 2
Progression-free survival time in the two groups mPFS: TACE + Sunitinib group, 15.6 months (95% CI 14.9–17.1 months); Sunitinib group, 10.9 months (95% CI 8.9–11.1 months).
Fig. 3
Fig. 3
Overall survival of patients in two groups mOS: TACE + Sunitinib group, 35.0 months (95% CI 32.7–37.4 months); Sunitinib group, 25.7 months (95% CI 23.6–27.8 months).
See this image and copyright information in PMC

References

    1. Randall JM, Millard F, Kurzrock R. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev. 2014 Dec;33(4):1109-24. doi: 10.1007/s10555-014-9533-1. PMID: 25365943. - PubMed
    1. Spadaccino F, Netti GS, Rocchetti MT, Castellano G, Stallone G, Ranieri E. [Diagnostic and prognostic markers of renal cell carcinoma]. G Ital Nefrol. 2020 Apr 9;37(2):2020-vol2. Italian. PMID: 32281759. - PubMed
    1. Pullen RL Jr. Renal cell carcinoma, part 1. Nursing. 2021 Jul 1;51(7):34–40. doi: 10.1097/01.NURSE.0000753972.19135.dc. PMID: 34156999. - PubMed
    1. Huang J, Leung DK, Chan EO, Lok V, Leung S, Wong I, Lao XQ, Zheng ZJ, Chiu PK, Ng CF, Wong JH, Volpe A, Merseburger AS, Powles T, Teoh JY, Wong MCS. A Global Trend analysis of kidney Cancer incidence and mortality and their Associations with Smoking, Alcohol Consumption, and metabolic syndrome. Eur Urol Focus. 2022 Jan;8(1):200–9. Epub 2021 Jan 23. PMID: 33495133. - PubMed
    1. Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019 Sep;16(9):539–552. doi: 10.1038/s41585-019-0211-5. Epub 2019 Jul 5. PMID: 31278395. - PubMed

MeSH terms